The Company is committed to developing new and innovative healthcare products catering to under-served disease areas and is currently in the process of completely revamping its drug discovery and development program. Initiatives involving the identification of fresh target areas, significant infrastructure creation and bringing in considerable expertise are all well underway. The goal is to be world - class in any of the therapies and target areas that the Company works in.

Lupin has a pipeline of six Investigational New Drugs (IND) addressing five different disease areas of Migraine, Psoriasis, Tuberculosis, Type 2 Diabetes and Rheumatoid Arthritis. These drug candidates are in various phases of clinical development.

click the image to zoom